UPDATED: Finerenone US Launch Analysis
Ahead of Bayer’s Kerendia (finerenone) investor webinar on Monday, November 15 @ 9 AM ET (view link to webcast), FENIX has conducted a follow-on launch analysis. In case you missed it, FENIX performed an early Kerendia launch and HCP website analysis in October 2021 (previous FENIX insight). Below, FENIX provides an analysis of the developing Kerendia Rx data, including a time-aligned launch comparison with other key brands to see if Kerendia’s launch is more like Entresto or Brilinta.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.